Vor Biopharma/VOR

$1.73

0%
-
1D1W1MYTD1YMAX

About Vor Biopharma

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Ticker

VOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Ang

Employees

168

Headquarters

Cambridge, United States

Vor Biopharma Metrics

BasicAdvanced
$122.79M
Market cap
-
P/E ratio
-$1.75
EPS
-
Beta
-
Dividend rate
$122.79M
$5.70
$1.62
313.81K
9.042
-47.38%
-58.74%
-50.28%
0.811
0.815
25.03%

What the Analysts think about Vor Biopharma

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
749.13% upside
High $22.00
Low $10.00
$1.73
Current price
$14.69
Average price target

Vor Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-26.2M
-20.85%
Profit margin
0%
-

Vor Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 22.52%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.43
-$0.45
-$0.49
-$0.39
-
Expected
-$0.38
-$0.43
-$0.47
-$0.50
-$0.38
Surprise
12.23%
4.09%
4.58%
-22.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vor Biopharma stock?

Vor Biopharma (VOR) has a market cap of $122.79M as of April 18, 2024.

What is the P/E ratio for Vor Biopharma stock?

The price to earnings (P/E) ratio for Vor Biopharma (VOR) stock is 0 as of April 18, 2024.

Does Vor Biopharma stock pay dividends?

No, Vor Biopharma (VOR) stock does not pay dividends to its shareholders as of April 18, 2024.

When is the next Vor Biopharma dividend payment date?

Vor Biopharma (VOR) stock does not pay dividends to its shareholders.

What is the beta indicator for Vor Biopharma?

Vor Biopharma (VOR) does not currently have a Beta indicator.

What is the Vor Biopharma stock price target?

The target price for Vor Biopharma (VOR) stock is $14.69, which is 749.13% above the current price of $1.73. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vor Biopharma stock

Buy or sell Vor Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing